Medical Grants
We are committed to supporting organizations that provide education and advocacy in our therapeutic areas of interest
We are committed to supporting organizations that provide education and advocacy in our therapeutic areas of interest
Ascendis Pharma is committed to supporting medical and scientific initiatives aligned with our goal of developing best-in-class therapeutics that address unmet medical needs and provide a meaningful improvement in patients’ lives.
Our focus is on organizations and medical societies that provide education, advocacy, and research in our therapeutic areas of interest. Ascendis Pharma cannot guarantee that any grant may be provided.
Examples of types of initiatives we may support include:
- Independent medical education funding or funding for Continuing Medical Education (CME) accredited events
- Support for a Grand Rounds presentation and/or educational opportunities for university fellows
- Funding for educational events organized by a patient organization for community outreach or disease awareness
For more information or to apply for a grant, please email: Grants@ascendispharma.com.
Growth Hormone Deficiency (GHD)
Growth hormone plays an essential role in the health of children and adults, promoting normal growth in children and maintenance of normal body composition and cardiometabolic health throughout adulthood1.
Pediatric GHD results from inadequate secretion of growth hormone from the anterior pituitary gland and is associated with short stature and delayed skeletal maturation2. Pediatric GHD can be congenital or acquired, idiopathic or have a known cause, and can be isolated or occur with multiple pituitary hormone deficiencies3. Daily somatropin has been the standard of care for decades, but registry data and surveys suggest that patients may have poor adherence, which is associated with suboptimal growth outcomes4.
In adults, growth hormone boosts protein production, promotes fat utilization, enhances muscle mass, and helps regulate blood sugar levels. Adult GHD is a rare disorder characterized by numerous metabolic abnormalities due to decreased or total loss of growth hormone production5. Symptoms and morbidity can include central obesity, metabolic syndrome, decreased bone density, alterations in lipid profile and markers of cardiovascular risk, fatigue, general weakness, lack of muscle tone, and psychological symptoms such as cognitive impairment, social isolation, lack of motivation, and depression6. Adult GHD is associated with economic burdens due to increased healthcare resource utilization, humanistic burdens due to loss of work productivity and unemployment, and the burden associated with comorbid conditions.
- Yuen, K.C.J., Biller, B.M.K., Radovick, S., Carmichael, J.D., Jasim, S., Pantalone, K.M. and Hoffman, A.R. (2019). American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care. Endocrine Practice, 25(11), pp.1191–1232. doi:https://doi.org/10.4158/gl-2019-0405.
- Grimberg, A., DiVall, S.A., Polychronakos, C., Allen, D.B., Cohen, L.E., Quintos, J.B., Rossi, W.C., Feudtner, C., Murad, M.H. and Society, on behalf of the D. and T.C. and E.C. of the P.E. (2016). Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Hormone Research in Paediatrics, [online] 86(6), pp.361–397. doi:https://doi.org/10.1159/000452150.
- Grimberg, A., DiVall, S.A., Polychronakos, C., Allen, D.B., Cohen, L.E., Quintos, J.B., Rossi, W.C., Feudtner, C., Murad, M.H. and Society, on behalf of the D. and T.C. and E.C. of the P.E. (2016). Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Hormone Research in Paediatrics, [online] 86(6), pp.361–397. doi:https://doi.org/10.1159/000452150.
- Thornton, P.S., Maniatis, A.K., Aghajanova, E., Chertok, E., Vlachopapadopoulou, E., Lin, Z., Song, W., Christoffersen, E.D., Breinholt, V.M., Kovalenko, T., Giorgadze, E., Korpal-Szczyrska, M., Hofman, P.L., Karpf, D.B., Shu, A.D. and Beckert, M. (2021). Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. The Journal of Clinical Endocrinology & Metabolism, [online] 106(11), pp.3184–3195. doi:https://doi.org/10.1210/clinem/dgab529.
- Thornton, P.S., Maniatis, A.K., Aghajanova, E., Chertok, E., Vlachopapadopoulou, E., Lin, Z., Song, W., Christoffersen, E.D., Breinholt, V.M., Kovalenko, T., Giorgadze, E., Korpal-Szczyrska, M., Hofman, P.L., Karpf, D.B., Shu, A.D. and Beckert, M. (2021). Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. The Journal of Clinical Endocrinology & Metabolism, [online] 106(11), pp.3184–3195. doi:https://doi.org/10.1210/clinem/dgab529.
- Mannstadt, M., Bilezikian, J.P., Thakker, R.V., Hannan, F.M., Clarke, B.L., Rejnmark, L., Mitchell, D.M., Vokes, T.J., Winer, K.K. and Shoback, D.M. (2017). Hypoparathyroidism. Nature Reviews Disease Primers, 3(1). doi:https://doi.org/10.1038/nrdp.2017.55.
Explore
